Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 10/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478511 | 0.84 | NPC1 (0.50) | PLA2G2ANPC1RAB9ATP53MEN1 | |
| SCHEMBL6480409 | 0.78 | PLA2G2A (0.60) | PLA2G2AMCHR1NPC1RAB9ATP53 | |
| SCHEMBL6479312 | 0.75 | KDM4E (0.58) | PLA2G2AGAA | |
| SCHEMBL6528779 | 0.67 | SIGMAR1 (0.50) | PLA2G2ATP53MEN1GAAKMT2A | |
| SCHEMBL9848807 | 0.67 | PLA2G2A (0.44) | PLA2G2AMCHR1NPC1RAB9AMEN1 | |
| SCHEMBL11039803 | 0.65 | MCHR1 (0.62) | PLA2G2AMCHR1NPC1RAB9AKMT2A | |
| SCHEMBL24802224 | 0.65 | ALDH1A1 (0.55) | NPC1RAB9ATP53HPGDHDAC6 | |
| SCHEMBL7986780 | 0.65 | F10 (0.62) | MCHR1MEN1KMT2AAPPHRH3 | |
| SCHEMBL26032908 | 0.64 | PLA2G2A (0.41) | PLA2G2ANPC1RAB9ATP53GAA | |
| SCHEMBL930649 | 0.64 | MCHR1 (0.56) | MCHR1NPC1RAB9ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
| EP-1456186-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A SB 2 /SB PHOSPHOLIPASE OF GROUP II | Yang Ji Chemical Company Ltd. (KR) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003048139-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A2 PHOSPHOLIPASE OF GROUP II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | PLA2G2A 35/4885MCHR1 3529/4885NPC1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.